228 related articles for article (PubMed ID: 11466355)
1. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens.
Qi L; Ostrand-Rosenberg S
J Immunol; 2001 Aug; 167(3):1371-8. PubMed ID: 11466355
[TBL] [Abstract][Full Text] [Related]
2. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens.
Golovkina T; Agafonova Y; Kazansky D; Chervonsky A
J Immunol; 2001 Feb; 166(4):2244-50. PubMed ID: 11160278
[TBL] [Abstract][Full Text] [Related]
3. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
[TBL] [Abstract][Full Text] [Related]
4. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
5. Quantitative relationship between MHC class II-superantigen complexes and the balance of T cell activation versus death.
Lavoie PM; McGrath H; Shoukry NH; Cazenave PA; Sékaly RP; Thibodeau J
J Immunol; 2001 Jun; 166(12):7229-37. PubMed ID: 11390471
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation.
Poncet P; Arock M; David B
J Leukoc Biol; 1999 Jul; 66(1):105-12. PubMed ID: 10410997
[TBL] [Abstract][Full Text] [Related]
7. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
Lamphear JG; Stevens KR; Rich RR
J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
[TBL] [Abstract][Full Text] [Related]
8. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules.
Thibodeau J; Labrecque N; Denis F; Huber BT; Sékaly RP
J Exp Med; 1994 Mar; 179(3):1029-34. PubMed ID: 8113671
[TBL] [Abstract][Full Text] [Related]
9. T cell receptor-major histocompatibility complex class II interaction is required for the T cell response to bacterial superantigens.
Labrecque N; Thibodeau J; Mourad W; Sékaly RP
J Exp Med; 1994 Nov; 180(5):1921-9. PubMed ID: 7964467
[TBL] [Abstract][Full Text] [Related]
10. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
11. Interactions between staphylococcal superantigens and MHC class II molecules.
Labrecque N; Thibodeau J; Sékaly RP
Semin Immunol; 1993 Feb; 5(1):23-32. PubMed ID: 8467091
[TBL] [Abstract][Full Text] [Related]
12. Activation with superantigens induces programmed death in antigen-primed CD4+ class II+ major histocompatibility complex T lymphocytes via a CD11a/CD18-dependent mechanism.
Damle NK; Leytze G; Klussman K; Ledbetter JA
Eur J Immunol; 1993 Jul; 23(7):1513-22. PubMed ID: 8100773
[TBL] [Abstract][Full Text] [Related]
13. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells.
Wen R; Cole GA; Surman S; Blackman MA; Woodland DL
J Exp Med; 1996 Mar; 183(3):1083-92. PubMed ID: 8642250
[TBL] [Abstract][Full Text] [Related]
14. Immune response to staphylococcal superantigens.
Krakauer T
Immunol Res; 1999; 20(2):163-73. PubMed ID: 10580640
[TBL] [Abstract][Full Text] [Related]
15. Different superantigens interact with distinct sites in the Vbeta domain of a single T cell receptor.
Hong SC; Waterbury G; Janeway CA
J Exp Med; 1996 Apr; 183(4):1437-46. PubMed ID: 8666902
[TBL] [Abstract][Full Text] [Related]
16. Proliferation of human T lymphocytes induced with superantigens is not dependent on costimulation by the CD28 counter-receptor B7.
Damle NK; Klussman K; Leytze G; Linsley PS
J Immunol; 1993 Feb; 150(3):726-35. PubMed ID: 7678619
[TBL] [Abstract][Full Text] [Related]
17. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
18. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
19. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo.
Ghumman B; Bertram EM; Watts TH
J Immunol; 1998 Oct; 161(7):3262-70. PubMed ID: 9759841
[TBL] [Abstract][Full Text] [Related]
20. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
